The use of biologics for the elbow: a critical analysis review.

J Shoulder Elbow Surg · Nov 2019 · Review

Dragoo JL, Meadows MC

Stanford University, Redwood City, CA

Shoulder & Elbow

SUMMARY — THE REDUCTIONThis critical review finds insufficient high-quality evidence to support biologic treatments like PRP for elbow conditions despite their popularity and cost.
Abstract, as published

There is significant interest in biologic treatment options to improve the healing environment and more rapidly decrease symptoms in many conditions around the elbow. Despite fairly widespread use of biologic agents such as platelet-rich plasma (PRP) in the elbow, there is a lack of clear evidence in the literature to support its use. The potential impact of these biologic agents must be evaluated with evidence from high-quality studies, particularly considering the high financial burden these treatments often impose on patients. The aim of this review is to provide an evidence-based summary of the biologic augmentation options available for use by the physician treating painful conditions of the elbow and to identify areas where further research is warranted.

Featured in the 2026-08-16 issue.

← Adhesive capsulitis of the shoulder: review of pathophysiolog…Post-traumatic elbow stiffness: Pathogenesis and current trea… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.